M Bailey-Hytholt Christina, Ulinski Gregory, Dugas Julia, Haines Mohammed, Lazebnik Mihael, Piepenhagen Peter, E Zarraga Isidro, Bandekar Amey
Biologics Drug Product Development & Manufacturing, Sanofi, Framingham, MA.
Global Discovery Pathology, Sanofi, Framingham, MA.
Curr Pharm Biotechnol. 2023 Apr 3. doi: 10.2174/1389201024666230403094238.
Lipid nanoparticles (LNPs) are one of the most clinically advanced candidates for delivering nucleic acids to target cell populations, such as hepatocytes. Once LNPs are endocytosed, they must release their nucleic acid cargo into the cell cytoplasm. For delivering messenger RNA (mRNA), delivery into the cytosol is sufficient; however, for delivering DNA, there is an added diffusional barrier needed to facilitate nuclear uptake for transcription and therapeutic effect.
Here, we use fluorescence microscopy to investigate the intracellular fate of different LNP formulations to determine the kinetics of localization to endosomes and lysosomes. LNPs used in the studies were prepared via self-assembly using a NanoAssemblr for microfluidic mixing. As the content of polyethylene glycol (PEG) within the LNP formulation influences cellular uptake by hepatocyte cells, the content and hydrocarbon chain length within the formulation were assessed for their impact on intracellular trafficking. Standard LNPs were then formed using three commercially available ionizable lipids, Dlin-MC3-DMA (MC3), Dlin-KC2-DMA (KC2), and SS-OP. Plasmid DNA (pDNA) and mRNA were used, more specifically with a mixture of Cyanine 3 (Cy3)-labeled and green fluorescence protein (GFP) producing plasmid DNA (pDNA) as well as Cy5-labeled GFP producing mRNA. After formulation, LNPs were characterized for the encapsulation efficiency of the nucleic acid, hydrodynamic diameter, polydispersity, and zeta potential. All standard LNPs were ~100 nm in diameter and had neutral surface charge. All LNPs resulted in encapsulation efficiency greater than 70%. Confocal fluorescence microscopy was used for the intracellular trafficking studies, where LNPs were incubated with HuH-7 hepatocyte cells at times ranging from 0-48 h. The cells were antibody-stained for subcellular components, including nuclei, endosomes, and lysosomes.
Analysis was performed to quantify localization of pDNA to the endosomes and lysosomes. LNPs with 1.5 mol% PEG and a hydrocarbon chain C14 resulted in optimal endosomal escape and GFP production. Results from this study demonstrate that a higher percentage of C14 PEG leads to smaller LNPs with limited available phospholipid binding area for ApoE, resulting in decreased cellular uptake. We observed differences in the localization kinetics depending on the LNP formulation type for SS-OP, KC2, and MC3 ionizable lipids. The results also demonstrate the technique across different nucleic acid types, where mRNA resulted in more rapid and uniform GFP production compared to pDNA delivery.
Here, we demonstrated the ability to track uptake and the sub-cellular fate of LNPs containing pDNA and mRNA, enabling improved screening prior to in vivo studies which would aid in formulation optimization.
脂质纳米颗粒(LNPs)是向诸如肝细胞等靶细胞群体递送核酸的临床进展最为显著的候选物之一。一旦LNPs被内吞,它们必须将其核酸货物释放到细胞质中。对于递送信使核糖核酸(mRNA),递送至细胞质就足够了;然而,对于递送DNA,还需要一个额外的扩散屏障来促进核摄取以实现转录和治疗效果。
在此,我们使用荧光显微镜来研究不同LNP制剂的细胞内命运,以确定其定位于内体和溶酶体的动力学。研究中使用的LNPs通过使用用于微流体混合的纳米组装器进行自组装制备。由于LNP制剂中聚乙二醇(PEG)的含量会影响肝细胞的细胞摄取,因此评估了制剂中的含量和烃链长度对细胞内运输的影响。然后使用三种市售的可电离脂质Dlin-MC3-DMA(MC3)、Dlin-KC2-DMA(KC2)和SS-OP形成标准LNPs。使用质粒DNA(pDNA)和mRNA,更具体地说是使用菁3(Cy3)标记的和产生绿色荧光蛋白(GFP)的质粒DNA(pDNA)的混合物以及Cy5标记的产生GFP的mRNA。制剂制备后,对LNPs进行核酸包封效率、流体动力学直径、多分散性和zeta电位的表征。所有标准LNPs的直径约为100nm,表面电荷呈中性。所有LNPs的包封效率均大于70%。共聚焦荧光显微镜用于细胞内运输研究,其中LNPs与HuH-7肝细胞在0至48小时的时间范围内孵育。对细胞进行亚细胞成分的抗体染色,包括细胞核、内体和溶酶体。
进行分析以量化pDNA定位于内体和溶酶体的情况。含有1.5mol%PEG和C14烃链的LNPs导致最佳的内体逃逸和GFP产生。本研究结果表明,较高百分比的C14 PEG会导致LNPs较小,与载脂蛋白E结合的可用磷脂面积有限,从而导致细胞摄取减少。我们观察到根据SS-OP、KC2和MC3可电离脂质的LNP制剂类型,其定位动力学存在差异。结果还证明了该技术适用于不同类型的核酸,与递送pDNA相比,mRNA导致GFP产生更快且更均匀。
在此,我们展示了追踪含有pDNA和mRNA的LNPs摄取和亚细胞命运的能力,这有助于在体内研究之前进行改进的筛选,从而有助于制剂优化。